Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21965733 | 0.88 | DDB1 (0.62) | CRBNDDB1 | |
| SCHEMBL26328295 | 0.83 | CRBN (0.54) | CRBNDDB1RAB9AALDH1A1MAPT | |
| SCHEMBL26328775 | 0.81 | RAB9A (0.45) | CRBNDDB1RAB9AALDH1A1MAPT | |
| SCHEMBL26328771 | 0.75 | CRBN (0.50) | CRBNDDB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL26328797 | 0.75 | CRBN (0.50) | CRBNDDB1ADAMTS5 | |
| SCHEMBL25567134 | 0.73 | DDB1 (0.54) | CRBNDDB1KDM4E | |
| SCHEMBL25567138 | 0.73 | DDB1 (0.51) | CRBNDDB1 | |
| SCHEMBL26328760 | 0.72 | DDB1 (0.71) | CRBNDDB1 | |
| SCHEMBL25567133 | 0.71 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL25567140 | 0.70 | DDB1 (0.48) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | CRBN 1/4885DDB1 319/4885RAB9A 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.